| Issue |
BIO Web Conf.
Volume 59, 2023
2023 5th International Conference on Biotechnology and Biomedicine (ICBB 2023)
|
|
|---|---|---|
| Article Number | 02021 | |
| Number of page(s) | 4 | |
| Section | Precision Medicine and Drug Development and Preparation | |
| DOI | https://doi.org/10.1051/bioconf/20235902021 | |
| Published online | 08 May 2023 | |
Plasma microRNAs levels associate with the outcome of ARDS patients
Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, No.87, Dingjiaqiao Road, Gulou District, Nanjing 210009, China
a sunqin1990seu@126.com
b* Correspondence: yz_huang@126.com
Background: Mesenchymal stem cells (MSC) are stromal cells with renew ability for multilineage differentiation. Therefore MSC has been considered as a therapy method for rebuilding alveoli structure and repairing the function of pulmonary vascular endothelial cells (VEC). However, whether MSC can play a therapeutic role in ARDS patients depends on different ARDS phenotypes. Recent studies about microRNAs (miRNAs) proved that miRNAs played important roles in MSC regulating function and activity of VEC which may affect therapeutic response and outcome to different ARDS patients, but few studies focused on this field. The purpose of our study is that plasma miRNAs regulated VEC’s function and specific miRNAs which were related to MSC and VEC (MSC‑VEC‑miRNAs) expressed differently between survival and non-survival ARDS patients. We aim to find specific MSC‑VEC‑miRNAs which are associated with the outcome of ARDS patients.
Methods: We obtained MSC-VEC-miRNAs through searching PUBMED database. A number of 101 ARDS patients were screened and 57 of them were included in our research within 24 hours of admission to ICU. We then collected their clinical data and their blood samples, then we did real-time PCR to test plasma levels of MSC-VEC-miRNAs.
Results: Fourteen MSC-VEC-miRNAs were selected in this study. We included 57 ARDS patients and 18(31.6%) of them died on Day 28 after diagnosis. Plasma miR-26a level in non-survival group was significantly lower than that in survival group (0.33[0.09-1.17] vs. 0.97[0.17-3.49], P=0.046). Plasma miR-320 level in non-survival group was significantly higher than that in survival group (0.37[0.16-1.66] vs. 0.18[0.07-0.39], P=0.041). There was no statistical difference of other 12 miRNA between two groups.
Conclusion: Plasma miR-26a and miR-320 levels have a certain predictive value for the prognosis of ARDS patients.
© The Authors, published by EDP Sciences, 2023
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.